Topi Geriolda, Ghatak Souvik, Satapathy Shakti Ranjan, Ehrnström Roy, Lydrup Marie-Louise, Sjölander Anita
Division of Cell Pathology, Skåne University Hospital, Lund University, Malmö, Sweden.
Division of Pathology, Department of Translational Medicine, Skåne University Hospital, Lund University, Malmö, Sweden.
Front Med (Lausanne). 2022 Mar 14;9:739620. doi: 10.3389/fmed.2022.739620. eCollection 2022.
We reported that high estrogen receptor beta (ERβ) expression is independently associated with better prognosis in female colorectal cancer (CRC) patients. However, estrogen receptor alpha (ERα) is expressed at very low levels in normal colon mucosa, and its prognostic role in CRC has not been explored. Herein, we investigated the combined role of ERα and ERβ expression in the prognosis of female patients with CRC, which, to the best of our knowledge, is the first study to investigate this topic. A total number of 306 primary CRCs were immunostained for ERα and ERβ expression. A Cox regression model was used to evaluate overall survival (OS) and disease-free survival (DFS). The combined expression of high ERβ + negative ERα correlates with longer OS (HR = 0.23; 95% CI: 0.11-0.45, <0.0001) and DFS (HR = 0.10; 95% CI: 0.03-0.26, < 0.0001) and a more favorable tumor outcome, as well as significantly higher expression of antitumorigenic proteins than combined expression of low ERβ + positive ERα. Importantly, we found that low ERβ expression was associated with local recurrence of CRC, whereas ERα expression was correlated with liver metastasis. Overall, our results show that the combined high ERβ + negative ERα expression correlated with a better prognosis for CRC patients. Our results suggest that the combined expression of ERα and ERβ could be used as a predictive combination marker for CRC patients, especially for predicting DFS.
我们报道过高雌激素受体β（ERβ）表达与女性结直肠癌（CRC）患者更好的预后独立相关。然而，雌激素受体α（ERα）在正常结肠黏膜中的表达水平非常低，其在CRC中的预后作用尚未得到探索。在此，我们研究了ERα和ERβ表达在女性CRC患者预后中的联合作用，据我们所知，这是第一项研究该主题的研究。总共306例原发性CRC进行了ERα和ERβ表达的免疫染色。使用Cox回归模型评估总生存期（OS）和无病生存期（DFS）。高ERβ + 阴性ERα的联合表达与更长的OS（HR = 0.23；95% CI：0.11 - 0.45，<0.0001）和DFS（HR = 0.10；95% CI：0.03 - 0.26，<0.0001）以及更有利的肿瘤结局相关，并且与低ERβ + 阳性ERα的联合表达相比，抗肿瘤蛋白的表达显著更高。重要的是，我们发现低ERβ表达与CRC的局部复发相关，而ERα表达与肝转移相关。总体而言，我们的结果表明高ERβ + 阴性ERα的联合表达与CRC患者更好的预后相关。我们的结果表明，ERα和ERβ的联合表达可作为CRC患者的预测性联合标志物，尤其是用于预测DFS。
